LONG-TERM T-CELL-MEDIATED IMMUNITY TO EPSTEIN-BARR VIRUS IN RENAL-ALLOGRAFT RECIPIENTS RECEIVING CYCLOSPORIN A
- 1 January 1981
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 317 (8210) , 10-13
- https://doi.org/10.1016/s0140-6736(81)90115-x
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- CYCLOSPORIN A AND EPSTEIN-BARR VIRUSThe Lancet, 1980
- Immunologic Phenotype in 30 Patients with Diffuse Large-Cell LymphomaNew England Journal of Medicine, 1980
- Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytesNature, 1980
- CYCLOSPORIN A IMMUNOSUPPRESSION, EPSTEIN-BARR ANTIBODY, AND LYMPHOMAThe Lancet, 1980
- HLA-restricted T-cell recognition of Epstein–Barr virus-infected B cellsNature, 1980
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980
- MALIGNANT LYMPHOMA IN CYCLOSPORIN A TREATED ALLOGRAFT RECIPIENTSThe Lancet, 1980
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979
- Neutralizing Antibodies to Epstein-Barr Virus in Healthy Populations and Patients with Infectious MononucleosisThe Journal of Infectious Diseases, 1973
- Cellular localization of an Epstein‐Barr virus (EBV)‐associated complement‐fixing antigen in producer and non‐producer lymphoblastoid cell linesInternational Journal of Cancer, 1973